Advancements in immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte antigen 4 (CTL-A4) have revolutionized NSCLC treatment [5,6]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.